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ABSTRACT
Cardiovascular disease is increased in individuals with type 1 or type 2 diabetes mellitus (DM). Left ventricular 
hypertrophy (LVH), which is an ominous prognostic sign and an independent risk factor for cardiac events, 
is often present in type 2 DM patients. The aim of our cross-sectional study was to evaluate the prevalence of 
LVH, and risk factors for its development, in normotensive type 2 diabetic patients without antihypertensive 
medication. The objectives of the study were to find out the prevalence of high left ventricular mass (LVM) 
in normotensive type 2 diabetic patients and compare it with nondiabetics and to uncover the risk factors for 
the development of high LVM in normotensive type 2 diabetic patients. A total of 130 age- and sex-matched 
subjects were selected (65 cases, diabetic normotensive, and 65 controls, nondiabetic normotensive) and baseline 
data were collected. LVM and left ventricular mass index (LVMI) were calculated using echocardigraphic 
parameters and body surface area. LVMI was significantly higher in patients with type 2 DM compared with 
age-, sex-matched healthy population (104.9 ± 21 vs. 78.5 ± 22.7 g/m2, respectively; P < 0.05). BMI, HbA1c, 
and duration of diabetes were significantly associated with LVH whereas sexes, age, PPBS, were not.
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INTRODUCTION
Cardiovascular disease is increased in individuals with 
type 1 or type 2 diabetes mellitus (DM). The Framingham 
Heart Study revealed a marked increase in peripheral 
arterial disease (PAD), congestive heart failure (CHF), 
coronary artery disease (CAD), myocardial infarction (MI), 
and sudden death (risk increase from one- to fivefold) in 
DM. Risk factors for macrovascular disease in diabetic 
individuals include dyslipidemia, hypertension, obesity, 
reduced physical activity, and cigarette smoking. Additional 
risk factors more prevalent in the diabetic population 
include microalbuminuria, macroalbuminuria, an elevation 
of serum creatinine, and abnormal platelet function.
Cardiovascular complications account for the highest 
mortality in diabetic patients, mainly due to CAD and 
CHF. Diabetes is associated with a high prevalence of 
hypertension, dyslipidemia, and microalbuminuria, all 
known independent cardiovascular risk factors. Even 
in populations with low cardiovascular risk, diabetes is 
associated with an increased incidence of cardiovascular 
death.[1]
Left ventricular hypertrophy (LVH), which is an ominous 
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prognostic sign and an independent risk factor for cardiac 
events, is often present in type 2 DM patients. The possible 
contributions of hyperinsulinemia and hyperglycemia to 
left ventricular mass (LVM) have been suggested in the 
normotensive and hypertensive subjects without diabetes 
but there have been few studies that examined the risk 
factors related to LVM in type 2 DM patients without 
hypertension.
Echocardiography provides a reliable noninvasive 
estimation of LVM and has been proven to be a more 
sensitive tool for the detection of LVH than other 
techniques. 
The aim of our cross-sectional study was to evaluate the 
prevalence of LVH, and risk factors for its development, 
in normotensive type 2 diabetic patients without 
antihypertensive medication.
The study had following aims: 
•  Comparison of LVM between normotensive diabetic 
and age- and sex-matched normotensive, nondiabetic 
populations. 
•  To evaluate the prevalence of LVH, and risk factors for 
its development, in normotensive type 2 DM patients 
without antihypertensive medication.
•  Determination of LVM in normotensive type 2 DM 
patients and age- and sex-matched, similar nondiabetic 
patients.
•  To find out the prevalence of high LVM in normotensive 
type 2 diabetic patients.
•  To uncover the risk factors for the development of high 
LVM in normotensive type 2 diabetic patients.
MATERIALS AND METHODS
This was a 1-year (from May 2008 to April 2009) hospital-
based, matched, cross-sectional, observational study 
based on clinical workup and investigations, and was 
conducted in Medical College and Hospital, Kolkata. The 
study population included patients from diabetes OPD, 
medicine OPD, and medicine wards. A total of 130 patients 
included 65 cases who were type 2 diabetes patients with 
normal blood pressure and a similar number of healthy, 
age- and sex-matched nondiabetic controls. The inclusion 
criteria were as follows: (1) patients on oral or injectable 
antidiabetic therapy among already diagnosed diabetic 
patients and (2) patients not on antidiabetic therapy but 
fulfilling the American Diabetic Association definition 
for DM. Exclusion criteria were as follows: (1) patients of 
known hypertension with and without drugs; (2) patients 
of known ischemic heart disease, CHF, cardiomyopathy, 
thyroid disorder, and renal involvement; (3) patients with 
COPD; and (4) known case type 1 DM and patients with 
dyslipedemia.
Parameters studied
Patient particulars such as age, sex, height, weight, 
body surface area (BSA), body mass index (BMI), and 
blood pressure were measured, and routine and relevant 
investigations like fasting blood glucose, postprandial blood 
glucose, HbA1c, serum urea and creatinine, urine RE/
ME, urinary albumin creatinine ratio (UACR), lipid profile, 
thyroid profile, chest x-ray, ECG, and echocardiography 
were also assessed.
Body mass index 
Estimation of BMI was done by taking weight in kilograms 
on a balance scale; the height was recorded in centimeters: 
BMI = WeIght (kg)/heIght (cM)  2
Body surface area (m2) 
BSA was measured using the following formula:  
(0.0001) × (71.84) × (Weight in kg) 0.425 × (Height in 
cm) 0.725
Blood pressure measurement
Recommended criteria for the diagnosis of hypertension 
are an average awake blood pressure of 135/85 mmHg and 
a sleeping blood pressure of 120/75 mmHg. These levels 
approximate a clinic blood pressure of 140/90 mmHg.
We have taken BP more than 140/90 mmHg as hypertensive 
and less than 140/90 mmHg as normotensive.
Laboratory investigations 
Fasting plasma glucose 
Venus blood samples were drawn in the morning following 
an overnight (minimum 8 h) fast and the oxalated blood 
sample was sent to the laboratory and was estimated using 
the GOD/POD method (Caltek Diagnostics Pvt. Ltd, 
India).
Postprandial plasma glucose 
An oral glucose tolerance test was performed 2 h after the 
ingestion of a standard 75 g of anhydrous glucose.
Serum urea was estimated by the urease-Berthelot method. 
For serum creatinine, the alkaline picrate (Jaffe’s reaction) 
method was used. Serum lipid levels were measured using 
Hitachi 912 analyzer. Routine and microscopic urine 
examinations were done in all cases. 
Hemoglobin A1c 
This was measured using boronate affinity chromatography 
by Micromat II (Biorad).52 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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Urinary albumin concentration 
Microalbuminuria estimation was done by the evaluation 
of the UACR. Normoalbuminuria was defined as a ratio 
less than 30.
Echocardiography
M-mode and pulsed Doppler echocardiography were 
performed according to the recommendations of the 
American Society of Echocardiography using Vingmed 
CFM725 equipped with a 3.25-MHz transducer.
Left ventricular dimensions
LV dimensions were measured from 2D-guided M-mode 
echocardiograms of the LV at the level of mitral leaflet 
tips or the papillary muscle using the parasternal view. The 
thicknesses of the left ventricular posterior wall and the 
ventricular septum (from the leading edge to the trailing 
edge) were measured. These values were used to calculate 
the LV mass. The LV end-diastolic and end-systolic 
dimensions were measured at the level of tips of the mitral 
leaflets as the largest and the smallest LV dimensions, 
respectively.
Left ventricular mass 
The following equation provides a reasonable determination 
of LVM in grams:
LV mass (ASE method) = 0.8 (1.04 ([LVID+PWT+IVST]3 
− [LVID]3)) + 0.6 g 
where LVID is the left ventricle internal dimension, 
PWT is the posterior wall thickness, IVST is the 
interventricular septal thickness, 1.04 is the specific gravity 
of the myocardium, and 0.8 is the correction factor. All 
measurements were made at end-diastole (at the onset of 
the R wave) in centimeters.[2]
For comparison, the LVM index (LVMI) was calculated by 
dividing the LVM with the surface area. Left ventricular 
wall motion was inspected in each of the 16 segments 
defined by the American Society of Echocardiography. All 
measurements were averaged over five cycles.
The upper limit of LVM was 162 g in females and 224 g 
in males.[3,4] The upper limit of the LVMI was 95 g/m2 in 
females and 115 g/m2 in males.[3,4]
Data collection in controls
In the age- and sex-matched healthy control group, 
anthropometric measurements were taken and fasting and 
postprandial blood sugar, urea, creatinine, urine albumin, 
ECG, chest x-ray, lipid profile, thyroid profile, and LVM 
by echocardiography were estimated.
Statistical methods
Data are expressed as mean ± SD for continuously 
distributed variables, and are in absolute numbers and 
percentages for the discrete variables.
Tests of significance
Unpaired Student’s t-test 
This is a statistical significance test for comparing one set 
of data with another, by comparing two means to see if 
they are significantly different, the data belonging to two 
different samples. 
Software developed by Open Source Epidemiologic 
Statistics for Public Health (version 2, OpenEpi) was used 
to perform a t-test (http://www.openepi.com). A P-value 
of <0.05 was considered significant.
Frequency table 
•  The frequency table procedure can be used for 
the followingTo test the hypothesis that for one 
classification table, all classification levels have the same 
frequency
•  To test the relationship between two classification 
factors.
In the frequency table dialog box, one or two discrete 
variables with the classification data must be identified. 
Classification data may be either numeric or alphanumeric 
(string) values.
Chi-square test
When we want to test the hypothesis that for one single 
classification table (e.g., gender), all classification levels 
have the same frequency, then we have to identify only 
one discrete variable in the dialog form. In this case, the 
null hypothesis is that all classification levels have the same 
frequency. If the calculated P-value is low (P<0.05), then the 
null hypothesis is rejected and the alternative hypothesis that 
there is a significant difference between the frequencies of 
the different classification levels must be accepted.
When we want to study the relationship between two 
classification factors (e.g., gender and profession), then we 
have to identify the two discrete variables in the dialog form. 
In this case, the null hypothesis is that the two factors are 
independent. If the calculated P-value is low (P<0.05), then 
the null hypothesis is rejected and the alternative hypothesis 
that there is a relation between the two factors is accepted. 
OpenEpi, version 2, was used to perform a chi-square test.53 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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RESULTS AND ANALYSIS
Demographic profile
To exclude the effect of age over LVM, people were 
selected from the same age group in both case and control 
groups. The range of age was 44–60 years with a mean 
age of 53 years.
Among 65 DM patients, there were 37 male patients and 
they constituted 56% of the total diabetic group; female 
patients were 28 in number and they constituted 44% of 
the total diabetic group. Male–female distribution was same 
in the control population.
All structural measurements of the left ventricle – left 
ventricular internal dimension in diastole [(LVID(D)], 
left ventricular posterior wall thickness (LVPWT), and 
interventricular septal thickness (IVST) – were higher in 
type 2 DM patients than control subjects and the difference 
was also statistically significant (P < 0.0001). The increased 
LVM and LVMI in cases can be explained by these   
[Table 2].
High LVMI means LVMI more than 115 g/m2 in the case 
of males and LVMI more than 95 g/m2 in the case of 
females means high LVMI [Tables 4–6]. 
DISCUSSION 
Heart disease occurs eventually in a majority of patients 
with DM and continues to be the outstanding factor in 
overall diabetic morbidity and mortality. Increased LVM 
may contribute to the increased cardiovascular risk because 
LVH is an ominous prognostic sign and an independent 
risk factor for sudden death, ventricular dysarrhythmia, 
Figure 1: Bar diagram showing prevalence of left ventricular mass in 
male subjects of Type 2 DM and control patients
Figure 2: Bar diagram showing prevalence of left ventricular mass 
index in male subjects of Type 2 DM and control patients
Table 1: Clinical and laboratory data of cases and controls
Variables Case Control t-value P-value
Age 53.000 ± 5.1113 52.815 ± 5.2823 0.202917 0.8395
BMI 23.912 ± 3.0217 22.691 ± 2.7668 2.41211 0.01728
BSA 1.679 ± 0.1472 1.633 ± 0.1574 1.7209 0.8768
FBS 132.769 ± 35.0953 99.569 ± 12.7303  7.16975 <0.0001
PPBS 216.462 ± 62.8518 125.769 ± 16.2652  11.2625 <0.0001
HbA1c 8.518 ± 1.2557 5.1108 ± 0.5354 20.132 <0.0001
BMI: Body mass index, BSA: Body surface area, FBS: Fasting blood sugar, PPBS: Post-prandial blood sugar
Table 2: Echocardiographic profile of diabetes mellitus patients and control subjects
Variables Diabetic patients with 
normotension (n  = 65)
Control subjects (n = 65) P-value
LV mass (g) 177.338 ± 43.3940 129.615 ± 45.8113 <0.0001
LVMI  104.9 ± 21.0 78.492 ± 22.7006 <0.0001
LVID in diastole (cm) 4.564 ± 0.2616 4.277 ± 0.5631 0.00029
IVST (cm) 1.094 ± 0.1335 0.915 ± 0.1778 <0.0001
Posterior wall thickness (cm) 1.062 ± 0.1454 0.9038 ± 0.1502 <0.0001
LVMI: Left ventricular mass index, LVID: Left ventricular internal dimension, IVST: Interventricular septal thickness54 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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myocardial ischemia, coronary heart disease and heart 
failure. Angiotensin-converting enzymes inhibitors are 
effective both in controlling blood pressure and reversing 
LVH.[5] Hypertension occurs about twice as often in 
individuals with diabetes as it does in the nondiabetic 
population, and up to 50% diabetic individuals become 
hypertensive.
Our cross-sectional study demonstrated LVH to be a 
common association in normotensive type 2 diabetic 
patients predominantly without micro- or macrovascular 
complications and hypertension compared to the age- 
and sex-matched, normotensive, nondiabetic control 
population. None of the patients were receiving 
antihypertensive medication. LVM was indexed to the 
BSA to avoid the influence of obesity. In this study, it was 
observed that the mean of LVM and LVMI was statistically 
significantly high in diabetic patients in comparison to 
healthy control subjects. This indicates the association of 
high LVM in patients of DM. Hirayama et al. from Japan 
demonstrated in their study that LVM and LVMI were 
significantly greater in the normotensive type 2 DM patients 
than the normotensive control population.[6] So our results 
are at par with that study.
The prevalence of high LVM and high LVMI in all type 2 
DM patients of our study was 44% and 53%, respectively. 
The prevalence of high LVM and high LVMI in male 
subjects with type 2 DM was 40% and 54%, respectively 
[Figure 1,2]. The prevalence of high LVM and high LVMI 
in female subjects with type 2 DM was 50% and 53%, 
respectively [Figure 3,4]. 
Tarnow et al. reported that the prevalence of LVH indexed   
by height2.7 was 43% (38–50%), and was similar in men and 
women in normotensive, normoalbuminuric type 2 DM 
patients.[7] In comparison with that study, the prevalence of 
LVH in our study was slightly higher. But they measured 
LVH indexed to  height2.7 instead of LVMI and they used 
the Penn formula for the calculation of LVM. 
In this research, we found that there is a significant difference 
in LVM between normotensive, normoalbuminuric type 
2 DM patients and the control group which must be 
noted because increased LVM is associated with increased 
cardiovascular morbidity and mortality and its early 
diagnosis and prevention is important; drug therapy can 
cause improvement in left ventricular function and can 
decrease cardiovascular morbidity. The high prevalence 
of LVH in diabetic patients supports this idea that early 
echocardiographic screening may be beneficial to these 
patients.
In our study it was also observed that the means of LVPWT, 
IVST, and LVID(D) were statistically significantly high in 
diabetic patients in comparison to healthy control subjects 
Table 3: Prevalence of LVMI in type 2 DM and control 
patients
LVMI Type 2 DM Control
High 35 (53%) 12 (18%)
Normal 30 (47%) 53 (82%)
Table 4: No. of subjects with high LVMI in type 2 DM 
and control patients
High LVMI Normal LVMI Total
Type 2 DM 35 30 65
Control  12 53 65
Table 5: Relation between duration of diabetes and 
LVMI
Duration of diabetes No of patients 
with high LVMI
No. of patients 
with normal LVMI
Less than 7 years 6 28
More than 7 years 23 8
Figure 3: Bar diagram showing prevalence of left ventricular mass in 
female subjects of Type 2 DM and control patients
Figure 4: Bar diagram showing prevalence of left ventricular mass 
index in female subjects of Type 2 DM and control patients55 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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[Table 2]. The increased thickness of the ventricular walls, 
in combination with the dilatation of the left ventricle, 
both contribute to the observed increase in LVM. This 
study shows that heart muscle disease complicates diabetes 
independently of hypertension.
The prevalence of LVH in the predominately nondiabetic 
population (95%) in the Framingham Heart Study assessed 
by echocardiography was reported to be 16% in men and 
21% in women. In that study, 42 women had diabetes and 
were characterized by an increased left ventricular wall 
thickness and a 22% greater LVM than their nondiabetic 
peers.
In our present study, the prevalence of LVH in the 
nondiabetic, normotensive control population was 18% in 
males and 17% in females [Figures 1,2]. These findings are 
consistent with the Framingham Heart Study.
None of our patients fulfilled the classical Sokolow-Lyon 
electrocardiogram criteria for LVH. This agrees with the 
Framingham Heart Study which demonstrated on ECG 
a LVH prevalence of 0.5%, applying the same method. 
In contrast, a recent Italian study reported a prevalence 
of ECG-LVH of 17% in type 2 diabetic patients.[8] 
These patients were, however, characterized by old age, 
long known duration of diabetes, arterial hypertension, 
and micro- or macroalbuminuria in nearly half of the 
population.
The prevalence of LVH increases with the severity of 
hypertension, ranging from 38% to 72% in hypertensive 
diabetic populations.[9] In the present study, nearby 50% 
of patients had LVH, even though none of the included 
type 2 diabetic patients was receiving or had prior treatment 
with antihypertensive medications, and all had an arterial 
blood pressure below the recommended cut-off of 140/90 
mmHg. While other studies have found a relationship 
between arterial blood pressure and LVM in diabetic 
patients with and without hypertension, this was not the 
case in the present study, where blood pressure levels were 
lower.
In the nondiabetic population, LVH is commonly 
associated with ischemic heart diseases and vice versa. 
However, evidence suggests that ischemic heart disease 
is a consequence rather than cause of LVH. Lee et al.[10] 
investigated a cohort of more than 5000 patients and found 
that the increased wall thickness of the ventricular septum 
or of the left ventricular posterior wall was not associated 
with prevalent coronary heart disease. Consequently, 
our findings of an increased wall thickness could not be 
explained by such a mechanism. 
Though this study was conducted with normotensive 
patients, it appeared clearly that features of diabetic 
cardiomyopathy were associated with increasing blood 
pressure levels. Increasing blood pressure could either be an 
etiologic factor or simply part of the hemodynamic features 
of diabetic cardiomyopathy as reported in experimental 
studies. An increased heart size may reflect the increase 
in the circulating blood volume, and systolic dysfunction 
could be secondary to increased peripheral resistance, as 
some studies have shown increasing peripheral resistance 
in diabetic patients. This could therefore be attributable to 
early changes preceding established hypertension.
In our study, type 2 diabetes patients with common risk 
factors for the development of LVH, such as hypertension, 
albuminuria, thyroid disorder, ischemic heart diseases, and 
dyslipedimia, were excluded from the study. But when 
compared, patients with a high LVMI had a higher BMI 
than the BMI of those with a normal LVMI. The LVMI 
also increased with the longer duration of diabetes and 
poor glycemic control as suggested by higher HbAIc in the 
Table 6: Clinical and laboratory characteristics of 65 normotensive type 2 diabetic patients not on antihypertensive 
medication, according to the left ventricular mass index
Variables  With high LVMI (n = 35) With normal LVMI (n = 30) P-value
Age  54 ± 5.3027 52 ± 4.7929 NS (0.1158)
BMI 24.74 ± 3.5712 23.24 ± 2.6780 0.045
BSA  1.71 ± 0.1526 1.65 ± 0.1382 NS (0.79)
Duration of diabetes 8.53 ± 1.6368 6.61 ± 1.2520 <0.0001
HbAIc 9.30 ± 0.7872 7.8861 ± 1.2107 <0.0001
FBS 150.55 ± 25.0793 118.44 ± 35.7203 NS (0.098)
PPBS 219.22 ± 59.9160 214.4167 ± 65.8931 NS (0.7401)
SBP 133.65 ± 6.0254 124.58 ± 8.8362 NS (0.7935)
DBP 82.2069 ± 5.2466 76.41 ± 4.993 NS (0.567)
LVMI: Left ventricular mass index, BMI: Body mass index, BSA: Body surface area, FBS: Fasting blood sugar, PPBS: Post-prandial blood sugar, SBP: Systolic blood pressure, 
DBP: Diastolic blood pressure56 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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diabetic population with LVH. Sato et al. also reported a 
significant correlation between glycemic control, duration 
of DM, and severity of nephropathy and LVMI.[11]
That urinary albumin excretion rate is strongly associated 
with the degree of LVM hypertrophy has been 
demonstrated in several previous studies of nondiabetics[12] 
and type 1 and type 2 diabetic patients with micro and   
macroalbuminuria.[13] Furthermore, in hypertensive 
diabetic and nondiabetic patients with LVH, an increased 
urinary albumin excretion rate resulted in an increased 
risk for cardiovascular morbidity and mortality.[14] But 
in our study we selected the patients from both diabetic 
and healthy control groups, those having no micro- and 
macroalbuminuria. So in this study, albuminuria was not 
the cause of LVH.
In addition to blood pressure, urinary albumin excretion 
rate, BMI, and blood glucose,[15] it has also been suggested 
that coronary microvascular dysfunction, endothelial 
dysfunction and chronic inflammation, and abnormalities 
in the tissue renin–angiotensin–aldosterone–bradykinin 
system or the encoding genes might play a role in the 
pathogenesis of LVH. The observation that some type 
2 diabetic patients have asymmetrical and some have 
concentric hypertrophy might suggest that the underlying 
pathology is not homogenous, but rather reflects the 
interaction of several of the above-mentioned risk factors.
CONCLUSION
Our cross-sectional study demonstrated the following:
•  LVM is significantly higher in type 2 diabetic patients 
without hypertension, albuminuria, and apparent 
ischemic heart disease as compared to healthy controls.
•  The prevalence of LVH is almost similar in both male 
and female patients. 
•  LVM in diabetic patients increases with BMI. So obese, 
type 2 DM patients have more chances of having LVH.
•  LVM in diabetic patients increases with the duration of 
diabetes. So patients with a longer duration of diabetes 
have more chances of having LVH.
•  LVM in diabetic patients also increases with the HbAIc 
level. So a poor glycemic control is also associated with 
more chances of having LVH.
•  Our small but significant study has thrown light on the 
prevalence of increased LVM in type 2 DM patients 
who are not otherwise suffer from hypertension, florid 
ischemic heart disease, and microvessel complications. 
So LVM evaluation is a mandatory workup in all type 2 
DM patients for the prognostication of morbidity and 
mortality. 
•  A large, prospective, double-blind study will further 
reveal the actual prevalence of LVM in such population. 
So our study in that sense is a sort of eye opener work.
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